AVR-RD-01, Fabry Gene Therapy, Continuing to Show Safety in Trials

AVR-RD-01, Fabry Gene Therapy, Continuing to Show Safety in Trials

316252

AVR-RD-01, Fabry Gene Therapy, Continuing to Show Safety in Trials

AVR-RD-01, an experimental gene therapy for Fabry disease, is continuing to show a positive safety profile in its clinical trials, with no serious adverse events related to the treatment reported, the therapy’s developer, Avrobio, announced in an update. These finding were presented at the 14th International Congress of Inborn Errors of Metabolism, held in Sydney, Australia. “It’s been exciting and rewarding to be part of this first-in-the-world clinical trial to bring this investigational gene therapy to…

You must be logged in to read/download the full post.